• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Hydrophobic-interaction chromatography for purification of influenza A and B virus

tetano

Editor, Senior Moderator
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Apr 1;1117:103-117. doi: 10.1016/j.jchromb.2019.03.037. [Epub ahead of print]
[h=1]Hydrophobic-interaction chromatography for purification of influenza A and B virus.[/h] Weigel T[SUP]1[/SUP], Soliman R[SUP]1[/SUP], Wolff MW[SUP]2[/SUP], Reichl U[SUP]3[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Options for hydrophobic-interaction chromatography (HIC) for purification of cell culture-derived influenza A and B virus have been assessed using a 96-well plate format using a semi-high-throughput approach. Follow-up experiments at preparative scale were used to characterize dynamic binding capacity, viral hemagglutinin protein (HA protein) recovery, and the influence of influenza virus (IV) strains on yield and contamination levels. Virus recoveries of up to 96% with a residual DNA level of about 1.3% were achieved. To achieve DNA contamination levels required for manufacturing of influenza vaccines for human use, a purification train comprising clarification, inactivation, concentration, column-based anion-exchange chromatography (AEC), and HIC was used in a final set-up. AEC using strong quaternary ammonium ligands was applied as an orthogonal method for DNA depletion by adsorption. Subsequently, HIC (with polypropylene glycol as functional group) was used to reversibly bind virus particles for capture and to remove residual contaminating DNA and proteins (flow-through). This two-step chromatographic process, which requires neither a buffer exchange step nor nuclease treatment had a total virus particle yield for IV A/PR/8/34 (H1N1) of 92%. The protein and the DNA contamination level could be reduced to 42% and at least 1.0%, respectively. With 17.2 μg total protein and 2.0 ng DNA per monovalent dose, this purity level complies with the limits of the European Pharmacopeia for cell culture-derived human vaccines. Overall, the presented downstream process represents a valuable alternative to existing virus purification schemes. Furthermore, it utilizes only off-the-shelf materials and is a simple as well as an economic process for production of cell culture-derived viruses and viral vectors.
Copyright ? 2019 Elsevier B.V. All rights reserved.


[h=4]KEYWORDS:[/h] 96-well semi-high-throughput screening (sHTS); Anion-exchange chromatography (AEC); Downstream process; Hydrophobic-interaction chromatography (HIC); Influenza virus vaccine purification process; Orthogonal

PMID: 31005703 DOI: 10.1016/j.jchromb.2019.03.037
 
Back
Top Bottom